Literature DB >> 10623516

Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.

Y Kliger1, Y Shai.   

Abstract

HIV-1 entry into its host cell is modulated by its transmembrane envelope glycoprotein (gp41). The core of the activated conformation of gp41 consists of a trimer of heterodimers comprising a leucine/isoleucine zipper sequence (represented here by the synthetic peptide N36 or by the longer N51 peptide) and a C-terminal highly conserved region (represented here by C34). A correlation was found between the action of DP178, which is a potent inhibitor of HIV-1 entry into its host cell, and its ability to interact with the leucine/isoleucine zipper sequence. This correlation was further tested and confirmed by circular dichroism spectroscopy. We found that whereas DP178 perturbs the partial alpha-helix nature of peptides corresponding to the leucine/isoleucine zipper sequence (N36 or N51), it cannot perturb the trimer of heterodimers conformation, modeled by the complex of N36 or N51 with C34. Therefore, we suggest that the already formed trimer of heterodimers is not the target of inhibition by DP178. Our results are consistent with a model in which DP178 acquires its inhibitory activity by binding to an earlier intermediate of gp41, in which the N and C peptide regions are not yet associated, thus allowing DP178 to bind to the leucine/isoleucine zipper sequence and consequently to inhibit transition to the fusion-active conformation. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623516     DOI: 10.1006/jmbi.1999.3368

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  31 in total

1.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.

Authors:  Lifeng Cai; Miriam Gochin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

4.  Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Authors:  Donna L Montgomery; Ying-Jie Wang; Renee Hrin; Micah Luftig; Bin Su; Michael D Miller; Fubao Wang; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jon Condra; Xiaomei Liu; Richard Hampton; Andrea Carfi; Antonello Pessi; Elisabetta Bianchi; Joseph Joyce; Chris Lloyd; Romas Geleziunas; David Bramhill; Vicki M King; Adam C Finnefrock; William Strohl; Zhiqiang An
Journal:  MAbs       Date:  2009-09-08       Impact factor: 5.857

5.  Stable interactions between the transmembrane domains of the adenosine A2A receptor.

Authors:  Damien Thévenin; Tzvetana Lazarova
Journal:  Protein Sci       Date:  2008-04-23       Impact factor: 6.725

Review 6.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

7.  Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.

Authors:  Gregory B Melikyan; Marc Egelhofer; Dorothee von Laer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor.

Authors:  Wen Yuan; Stewart Craig; Zhihai Si; Michael Farzan; Joseph Sodroski
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.

Authors:  Alonso Heredia; Bruce Gilliam; Olga Latinovic; Nhut Le; Douty Bamba; Anthony Devico; Gregory B Melikyan; Robert C Gallo; Robert R Redfield
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

10.  The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex.

Authors:  Berend Jan Bosch; Ruurd van der Zee; Cornelis A M de Haan; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.